{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015415","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.090413+00:00","generated_at":"2026-06-15T21:41:20.616526+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"X4 Pharma Q1 net loss $24.0M; cash $94.4M into Q2 2024; mavorixafor NDA on track","bullets":["Net loss of $24.0M in Q1 2023 vs $22.0M in Q1 2022; R&D expenses $22.1M including $5.0M milestone accrual.","Cash, equivalents & restricted cash $94.4M as of March 31, 2023; sufficient to fund operations into Q2 2024.","U.S. NDA submission for mavorixafor in WHIM syndrome on track for early second half of 2023.","Phase 3 WHIM trial infection data to be presented at May 16 webinar and May 21 CIS oral presentation.","Phase 2 chronic neutropenia trial data and regulatory path clarity expected in Q2/Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015415","json":"https://secwatch.observer/filing/0001628280-23-015415.json","markdown":"https://secwatch.observer/filing/0001628280-23-015415.md","text":"https://secwatch.observer/filing/0001628280-23-015415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023015415/0001628280-23-015415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023015415/xfor-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:41:20.616526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30d825b89d14be5eee63d596f5aef2783ab9fcdb","claim":"X4 Pharmaceuticals, Inc reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"On May 4, 2023, X4 Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results and other business highlights for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023015415/0001628280-23-015415-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}